Content Conference Coverage Conferences CROI 2015
CROI 2015: Retrovirus Conference Now Underway in Seattle
- Details
- Category: HIV Treatment
- Created on Monday, 23 February 2015 00:00
The 2015 Conference on Retroviruses and Opportunistic Infections (CROI) takes place this week, February 23-26, at the Washington State Convention Center in Seattle. CROI focuses on HIV treatment, prevention, and basic science. For the past several years it has also included substantial hepatitis C content, and this year will feature presentations on Ebola virus. HIVandHepatitis.com is on site in Seattle all week bringing you news coverage and Twitter updates (@HIVandHepatitis).
CROI 2015: Does Emtricitabine Work Better than Lamivudine in Combination ART?
- Details
- Category: Approved HIV Drugs
- Created on Friday, 20 March 2015 00:00
People with HIV who started an antiretroviral regimen containing emtricitabine (FTC; Emtriva) and NNRTIs were about half as likely to experience virological treatment failure as those who used the similar drug lamivudine (3TC; Epivir), according to an analysis of more than 6000 participants in the Dutch ATHENA cohort presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. No significant differences between emtricitabine and lamivudine were seen with boosted protease inhibitor regimens.
CROI 2015: Cabotegravir and Rilpivirine Effective for HIV Maintenance Therapy at 96 Weeks
- Details
- Category: Experimental HIV Drugs
- Created on Tuesday, 17 March 2015 00:00
A combination of 2 once-daily oral antiretrovirals -- the next-generation integrase inhibitor cabotegravir (GSK1265744) and the approved NNRTI rilpivirine -- was as effective as an efavirenz-based regimen when used as maintenance therapy to keep viral load suppressed, according to a poster presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
CROI 2015: Antiretroviral Therapy -- Past, Present and Future [VIDEO]
- Details
- Category: Approved HIV Drugs
- Created on Monday, 09 March 2015 00:00
Antiretroviral therapy (ART) has undergone a remarkable evolution from AZT monotherapy in the late 1980s, to effective combination therapy in the mid-1990s, to today's well-tolerated single-tablet regimens. But questions about the optimal time to start treatment remain unanswered and getting ART to everyone who needs it is still a challenge, according to a presentation by David Cooper at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
CROI 2015: Antiretrovirals in the Pipeline: New Tenofovir and HIV Maturation Inhibitor [VIDEO]
- Details
- Category: Experimental HIV Drugs
- Created on Thursday, 05 March 2015 00:00
Tenofovir alafenamide, a new formulation that works as well as the current formulation but is easier on the kidneys and bones, and BMS-955176, a maturation inhibitor that prevents HIV from producing complete new infectious virus, were among the novel antiretroviral drugs discussed at the 2015 Conference on Retroviruses and Opportunistic Infections(CROI) last week in Seattle.
More Articles...
- CROI 2015: Tenofovir Alafenamide as Effective but Safer for Kidneys and Bones than TDF
- CROI 2015: Putting On Too Much Weight After Starting ART Increases Chronic Inflammation
- CROI 2015: Experimental Agents Reverse HIV Latency, Help Immune System Fight Infected Cells
- CROI 2015: Researchers Discuss HIV Cure Strategies
- CROI 2015: Early Antiretroviral Treatment Reduces, but Does Not Eliminate HIV Reservoir
- CROI 2015: We May Need to Combine Many Approaches to Achieve a Cure for HIV
- CROI 2015: The Quest for a Cure for HIV [VIDEO]
- CROI 2015: Financial Incentives Did Not Improve Linkage to Care or HIV Viral Suppression
- CROI 2015: Treatment Cascades and Viral Load Surveys Inform ART as Prevention in Africa
- CROI 2015: HIV Care in New York City [VIDEO]
- CROI 2015: No HIV Transmissions from HIV+ Partners Seen in Australian Gay Couples Study
- CROI 2015: Combining PrEP and ART Could Nearly Eliminate HIV Infection
- CROI 2015: Daily PrEP Leads to Better Adherence and Protective Drug Levels in Women
- CROI 2015: PrEP Provides 86% Protection in 2 Studies [VIDEO]
- CROI 2015: Maraviroc Levels in Vaginal and Rectal Tissues May Not Be High Enough for PrEP
- CROI 2015: PrEP Use Rising in San Francisco, but Scale-Up Could Cut New Infections
- CROI 2015: PrEP Stops 86% of HIV Infections in PROUD Study
- CROI 2015: On-Demand PrEP Prevents 86% of HIV Infections in Ipergay
- CROI 2015: European PrEP Studies Find High and Equivalent HIV Protection
- CROI 2015: PEPFAR Abstinence and Faithfulness Funding Had No Impact on Sexual Behavior in Africa
- CROI 2015: Disappointing Result for Tenofovir Gel Microbicide
- CROI 2015: Tenofovir Vaginal Gel Not Effective Overall Against HIV [VIDEO]
- CROI 2015: Circumcision is Reducing HIV Incidence in Uganda, Rakai Community Study Shows
- CROI 2015: Inflammation and Gut Damage Persist in People with HIV Despite Early ART
- CROI 2015: Stopping Co-trimoxazole During ART Raises Risk of Bacterial Illness and Malaria
- CROI 2015: Cardiovascular Risk Factors for HIV-Positive People
- CROI 2015: Cardiovascular Risk Factors for HIV-Positive People
- CROI 2015: Cardiovascular Disease Among People with HIV
- CROI 2015: Predicting Cardiovascular Disease in People with HIV -- Can We Do Better?
- CROI 2015: Statins May Reduce Risk of Heart Disease in People with HIV
- CROI 2015: Does HIV Make You Fat? Study Connects Viral Load with Fat Gains
- CROI 2015: Tenofovir, Atazanavir & Lopinavir Associated with Raised Risk of Chronic Kidney Disease
- CROI 2015: FRAX Fracture Prediction Tool Underestimates Fracture Risk in Men with HIV
- CROI 2015: Smoking Outweighs HIV-Related Risk Factors for Non-AIDS Cancers
- CROI 2015: Screening Finds High Prevalence of Early-Stage Lung Cancer in Smokers with HIV
- CROI 2015: Varenicline Helps People with HIV Stop Smoking, but Success Rate Remains Low
- CROI 2015: Smoking and Its Detrimental Outcomes for People with HIV
- CROI 2015: Study Finds High Rates of Cancer Among Elderly People with HIV
- CROI 2015: Similar Fat Gain Seen with Different Antiretroviral Regimens [VIDEO]
- CROI 2015: Levonorgestrel Contraception May Be Less Effective for Women Taking Efavirenz
- CROI 2015: Breastfeeding Mothers with HIV Often Undiagnosed in Sub-Saharan Africa
- CROI 2015: Triple-Drug Combination Superior for Preventing Mother-to-Child HIV Transmission
- CROI 2015: 3-Drug ART Prevents Vertical HIV Transmission [VIDEO]
- CROI 2015: Re-infection Due to Ongoing Risk Is Probably the Cause of HCV Recurrence After SVR
- CROI 2015: Sustained Virological Response Represents a Long-term Cure for Hepatitis C
- CROI 2015: Hepatitis C -- Mission Accomplished? [VIDEO]
- CROI 2015: Hepatitis C -- A Light at the End of the Tunnel [VIDEO]
- CROI 2015: Good Sofosbuvir/Ledipasvir Adherence in SYNERGY and ERADICATE Trials
- CROI 2015: HCV Sexual Transmission Linked to Anal Sex, Drug Use, Lower CD4 Count
- CROI 2015: Liver Disease Progression Is Common Among Baby Boomers with Hepatitis C
- CROI 2015: HCV Viral Load and Speed of Decline Do Not Predict Cure with Interferon-Free Therapy
- CROI 2015: End-Stage Liver Disease Among HIV+ People with Hepatitis B or C
- CROI 2015: Sofosbuvir/Ledipasvir May Alter Antiretroviral Levels in HIV/HCV Coinfected People
- CROI 2015: Deferring Hepatitis C Treatment Can Lead to Liver Cancer and Death
- CROI 2015: Interferon-Free Regimens Show High Cure Rates for HIV/HCV Coinfected
- CROI 2015: High-Dose Rifampin Shortens Time to Tuberculosis Clearance
- CROI 2015: XDR-TB in South Africa is Largely Spread Person-to-Person, Not By Treatment Failure
- CROI 2015: XDR TB Transmission in High-HIV-Prevalence Settings [VIDEO]
- CROI 2015: Early ART and Isoniazid Preventive Therapy Reduce Risk of Illness and Death in Africa
- CROI 2015: Screening May Miss Pre-cancerous Anal Lesions in Women with HIV
- CROI 2015: International Ebola Response Too Little, Too Late [VIDEO]
Web Design and Development by